ZTS:NYSE

Zoetis (ZTS) is trading at $122.36, which sits below its 20‑day (126.9) and 50‑day (126.0) simple moving averages, indicating short‑term weakness. The 14‑day RSI of 41 suggests the stock is edging toward oversold territory but not yet in the classic oversold zone. A bearish MACD histogram (-0.85) and a negative divergence from the signal line reinforce the technical downside bias. Nevertheless, the price remains comfortably above the identified support at $118.28, providing a near‑term floor. Fundamental metrics paint a mixed picture: the trailing PE of 20.3 is well below the industry average of 25.4, hinting at relative cheapness, while the price‑to‑book of 15.6 appears stretched. The company delivers robust profitability—gross margin 72%, operating margin 35% and an extraordinary ROE of 66%—and supports a 1.73% dividend with a modest 33% payout ratio, making the dividend sustainable.
Recent analyst sentiment is upbeat, with Bank of America lifting its price target to $140 and citing a strong Q4 and a solid fiscal‑2026 outlook. The consensus “Buy” rating from 16 analysts and a median target of $145 imply roughly 20% upside from current levels. However, the balance sheet is levered, featuring a debt‑to‑equity of 280 and total debt exceeding cash by $7 billion, which elevates financial risk. Volatility remains high at 26% over the past 30 days and volume trends are decreasing, adding to market‑timing uncertainty. The low beta (~0.75) suggests limited systematic risk, but sector‑specific regulatory scrutiny and the company’s reliance on the U.S. market introduce medium‑level regulatory and geographic risks. We therefore view ZTS as a fundamentally solid animal‑health franchise with short‑term technical headwinds, moderate upside potential, and a dividend that can be counted on.